PCM
PTCT icon

Pentwater Capital Management’s PTC Therapeutics PTCT Stock Holding History

Pentwater Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,000
Closed -$609K – 182
2015
Q1 		$609K Buy
+10,000
New +$610K ﹤0.01% 146

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Pentwater Capital Management's PTCT Position: Q2 2015 in Review

Pentwater Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2015, closing a stake of 10,000 shares — an estimated $609K sold.

Pentwater Capital Management first reported a position in PTCT in Q1 2015 and held it in 1 quarter. The position peaked at $609K in Q1 2015. 155 funds tracked by Wall St. Rank hold PTCT as of Q2 2015.

  • Pentwater Capital Management reported no remaining PTC Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Pentwater Capital Management sold 10,000 PTC Therapeutics shares in Q2 2015, an estimated $609K.
  • Pentwater Capital Management first reported a position in PTC Therapeutics in Q1 2015 and held it in 1 quarter.
  • Pentwater Capital Management's PTC Therapeutics position peaked at $609K in Q1 2015.
  • 155 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2015.

Based on Pentwater Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.